Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Recruiting

Phase 1

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic MalignanciesTolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Sponsor:

Vanda Pharmaceuticals

Code:

NCT03838926

Conditions

Relapsed or Refractory Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Trichostatin A

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-02. This information was provided to ClinicalTrials.gov by Vanda Pharmaceuticals on 2019-02-15.